サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1747924

風疹ワクチンの世界市場

Rubella Vaccines

出版日
ページ情報
英文 275 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.35円
風疹ワクチンの世界市場
出版日: 2025年06月13日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 275 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

風疹ワクチンの世界市場は2030年までに2億2,110万米ドルに達する見込み

2024年に1億8,670万米ドルと推定される風疹ワクチンの世界市場は、分析期間2024-2030年にCAGR 2.9%で成長し、2030年には2億2,110万米ドルに達すると予測されます。本レポートで分析したセグメントの1つである一価製剤は、CAGR 4.0%を記録し、分析期間終了時には9,530万米ドルに達すると予測されます。麻疹風疹ワクチン分野の成長率は、分析期間中CAGR 1.4%と推定されます。

米国市場は5,090万米ドルと推定され、中国はCAGR 5.6％で成長すると予測される

米国の風疹ワクチン市場は、2024年に5,090万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに4,360万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは5.6%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.0％と2.2％と予測されています。欧州では、ドイツがCAGR 1.6%で成長すると予測されています。

世界の「風疹ワクチン」市場- 主要動向と促進要因まとめ

なぜ風疹ワクチン接種は世界的に公衆衛生の優先事項であり続けるのか？

風疹は小児や成人では軽症であることが多いが、妊婦が感染すると胎児に壊滅的な脅威を与え、先天性風疹症候群（CRS）を引き起こします。CRSを予防する最も効果的な方法は、風疹の予防接種、特に麻疹・おたふくかぜ・風疹（MMR）混合ワクチンの接種を広く行うことです。予防接種プログラムは世界的に風疹罹患率の減少に目覚ましい進歩を遂げているが、特にヘルスケアのインフラが脆弱な地域やワクチン接種をためらう地域では、まだ格差が残っています。風疹ワクチン接種の重要性は、ウイルスを制御するだけでなく、CRSによる長期障害を減らすことにもあります。WHOとユニセフが調整する世界的キャンペーンは、2030年までに風疹をMMRの普遍的接種範囲に組み込むことを目指しています。高所得国は風疹をほぼ撲滅しているが、アフリカや東南アジアの一部では、集団予防接種キャンペーンや妊産婦の健康プログラムを通じて取り組みを拡大しています。

混合ワクチンと新たな物流モデルは、アクセスを広げているか？

MMRとMR（麻疹風疹）混合ワクチンの普及により、予防接種スケジュールが簡素化され、接種率が向上しました。これらの多価ワクチンは、診療所の受診回数を減らし、保管の必要性を削減し、コンプライアンスを向上させる。マイクロニードルパッチ、皮内注射器、耐熱性製剤などの技術革新は、ラストワンマイルデリバリーの課題に対処しています。さらに、Gaviとの共同イニシアティブにより、低所得国でもMMR接種の補助金とヘルスケア従事者のトレーニングが受けられるようになっています。ワクチンの備蓄戦略、コールドチェーンの拡大、移動医療ユニットも、遠隔地のコミュニティにおけるアウトリーチを改善しています。これらの開発により、風疹ワクチンの普及が進むだけでなく、特に乳幼児と思春期の女児を対象とした定期予防接種スケジュールに、より一貫した形で組み込むことが可能となっています。

サーベイランスと血清学的検査は風疹の世界的撲滅に役立つか？

サーベイランスとラボ検査は、風疹撲滅を検証し、リスクのある地域を特定する上で極めて重要です。デジタル登録と検査室ネットワークに支えられたリアルタイムの監視システムは、アウトブレイクやCRS症例の迅速な検出を可能にします。血清学的調査は集団免疫の評価に役立ち、的を絞った予防接種活動の指針となります。日本、英国、韓国などの国々では、包括的なサーベイランス・データを活用して、特に小児期に予防接種を受けなかった成人男性に対する予防接種戦略を微調整しています。サーベイランスはまた、ワクチンの有効性を経時的に把握することにも役立ち、医療制度が必要に応じてブースター・キャンペーンを計画するのに役立っています。風疹サーベイランスを麻疹排除プログラムと調和させることは、共通の公衆衛生の枠組みの下で、二重のウイルス制御を達成する相乗的な道筋を提供します。

保健システム全体における風疹ワクチン接種拡大の原動力は？

世界の風疹ワクチン市場の成長の原動力は、世界の出生率の上昇、混合ワクチンの統合の増加、公衆衛生の義務付け強化など、いくつかの要因による。特にアジア太平洋、アフリカ、ラテンアメリカの国家予防接種プログラムでは、定期接種と追加接種の両方を通じてMMR/MRワクチンの接種を拡大しています。新しいMRワクチンの規制当局による承認や各地域の製造イニシアティブにより、現地での入手が容易になり、コストが削減されています。国際保健機関とワクチン製造業者間の戦略的パートナーシップにより、供給インフラが強化されています。さらに、公衆衛生メッセージや妊産婦スクリーニングプログラムにより、ヘルスケア提供者や出産適齢期の女性の間で風疹に対する認識が高まっています。デジタル医療システムは、予防接種率を追跡し、リスクの高い集団におけるギャップを明らかにするのに役立っています。

セグメント

タイプ別（一価製剤,麻疹風疹ワクチン,麻疹/おたふくかぜ/風疹ワクチン,麻疹おたふくかぜ風疹水痘ワクチン）;エンドユーザー別（病院, NGO,小児科クリニック,その他のエンドユーザー）

調査対象企業の例（注目の32社）

  • Abbott Laboratories
  • AstraZeneca plc
  • Bavarian Nordic
  • Bharat Biotech
  • Biological E. Limited
  • Cadila Healthcare（Zydus Cadila）
  • Chumakov Federal Scientific Center
  • CSL Seqirus
  • GlaxoSmithKline plc
  • Haffkine Bio-Pharmaceutical Corporation Ltd.
  • Indian Immunologicals Limited
  • Institute of Poliomyelitis and Viral Encephalitides
  • Merck & Co., Inc.
  • Panacea Biotec Ltd.
  • Pfizer Inc.
  • Sanofi S.A.
  • Serum Institute of India Pvt. Ltd.
  • Sinovac Biotech Ltd.
  • Takeda Pharmaceutical Company Limited
  • Wockhardt Ltd.

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・業界団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP35693

Global Rubella Vaccines Market to Reach US$221.1 Million by 2030

The global market for Rubella Vaccines estimated at US$186.7 Million in the year 2024, is expected to reach US$221.1 Million by 2030, growing at a CAGR of 2.9% over the analysis period 2024-2030. Monovalent Formulation, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$95.3 Million by the end of the analysis period. Growth in the Measles-Rubella Vaccine segment is estimated at 1.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$50.9 Million While China is Forecast to Grow at 5.6% CAGR

The Rubella Vaccines market in the U.S. is estimated at US$50.9 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$43.6 Million by the year 2030 trailing a CAGR of 5.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.0% and 2.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.6% CAGR.

Global "Rubella Vaccines" Market - Key Trends & Drivers Summarized

Why Does Rubella Vaccination Remain a Public Health Priority Globally?

Rubella, often mild in children and adults, poses a devastating threat to unborn children when pregnant women become infected, leading to congenital rubella syndrome (CRS). The most effective way to prevent CRS is widespread rubella vaccination, particularly through the measles-mumps-rubella (MMR) combined vaccine. Immunization programs have made remarkable progress in reducing rubella incidence globally, yet gaps remain-especially in regions with weak healthcare infrastructure or vaccine hesitancy. The importance of rubella vaccination lies not only in controlling the virus but also in reducing long-term disabilities caused by CRS. Global campaigns coordinated by WHO and UNICEF aim to integrate rubella into universal MMR coverage by 2030. High-income countries have nearly eliminated rubella, while parts of Africa and Southeast Asia are scaling up efforts through mass vaccination campaigns and maternal health programs.

Are Combination Vaccines and New Logistics Models Broadening Access?

The widespread use of MMR and MR (measles-rubella) combination vaccines has simplified immunization schedules and enhanced coverage. These multivalent vaccines reduce clinic visits, cut storage needs, and increase compliance. Innovations like micro-needle patches, intradermal injectors, and thermostable formulations are addressing last-mile delivery challenges. Additionally, collaborative initiatives with Gavi are enabling low-income countries to receive subsidized MMR doses along with training for healthcare workers. Vaccine stockpile strategies, cold chain expansion, and mobile health units are also improving outreach in remote communities. These developments are not only increasing rubella vaccine penetration but also enabling more consistent integration into routine immunization schedules, especially for infants and adolescent girls.

Can Surveillance and Serological Testing Help Eliminate Rubella Globally?

Surveillance and lab testing are critical in verifying rubella elimination and identifying regions at risk. Real-time monitoring systems, supported by digital registries and lab networks, enable prompt detection of outbreaks and CRS cases. Serological surveys help assess population immunity, guiding targeted immunization drives. Countries like Japan, the UK, and South Korea have leveraged comprehensive surveillance data to fine-tune their vaccination strategies, especially for adult men who may have missed childhood immunization. Surveillance also aids in understanding vaccine efficacy over time, helping health systems plan booster campaigns if needed. The harmonization of rubella surveillance with measles elimination programs offers a synergistic pathway to achieving dual viral control under shared public health frameworks.

What’s Powering the Expansion of Rubella Vaccination Across Health Systems?

The growth in the global rubella vaccines market is driven by several factors including rising global birth rates, increasing integration of combination vaccines, and stronger public health mandates. National immunization programs, particularly in Asia-Pacific, Africa, and Latin America, are scaling up MMR/MR vaccine delivery through both routine and supplemental immunization activities. Regulatory approvals of newer MR variants and regional manufacturing initiatives are boosting local availability and reducing costs. Strategic partnerships between international health agencies and vaccine producers are enhancing delivery infrastructure. Moreover, public health messaging and maternal screening programs are increasing rubella awareness among healthcare providers and women of childbearing age. Digital health systems are helping track immunization coverage and flag gaps in high-risk populations, further

SCOPE OF STUDY:

The report analyzes the Rubella Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine, Measles Mumps Rubella Varicella Vaccine); End-Use (Hospitals, NGOs, Pediatric Clinics, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

  • Abbott Laboratories
  • AstraZeneca plc
  • Bavarian Nordic
  • Bharat Biotech
  • Biological E. Limited
  • Cadila Healthcare (Zydus Cadila)
  • Chumakov Federal Scientific Center
  • CSL Seqirus
  • GlaxoSmithKline plc
  • Haffkine Bio-Pharmaceutical Corporation Ltd.
  • Indian Immunologicals Limited
  • Institute of Poliomyelitis and Viral Encephalitides
  • Merck & Co., Inc.
  • Panacea Biotec Ltd.
  • Pfizer Inc.
  • Sanofi S.A.
  • Serum Institute of India Pvt. Ltd.
  • Sinovac Biotech Ltd.
  • Takeda Pharmaceutical Company Limited
  • Wockhardt Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Rubella Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Global Focus on Eradication of Congenital Rubella Syndrome Drives Vaccination Efforts
    • Integration of Rubella with Measles and Mumps Vaccines Expands Market Reach
    • WHO and UNICEF Campaigns Propel Coverage in Low- and Middle-Income Countries
    • National Immunization Programs Reinforce Market Demand for Rubella-Containing Vaccines
    • Increased Availability of Combination Vaccines Simplifies Public Health Deployment
    • School Entry Mandates and Routine Immunization Policies Sustain Pediatric Demand
    • Improved Cold Chain Infrastructure Supports Widespread Vaccine Distribution
    • Rising Seroprevalence Studies Highlight Gaps in Immunity and Drive Catch-Up Campaigns
    • Regulatory Approvals for Combination Formulations Enhance Procurement Appeal
    • Ongoing Public Health Surveillance Throws the Spotlight on Outbreak Prevention Strategies
    • Private Sector Participation in Immunization Clinics Generates Supplemental Demand
    • Global Health Goals and SDG Targets Accelerate Government Commitments
    • Innovations in Thermostable Vaccines Expand Access in Rural and Remote Regions
    • Growing Support for Adolescent and Adult Immunization Policies Expands Demographic Reach
    • Donor and NGO Funding Channels Create New Avenues for Market Expansion
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Rubella Vaccines Market Analysis of Annual Sales in US$ for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Rubella Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Rubella Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Rubella Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Monovalent Formulation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Monovalent Formulation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Monovalent Formulation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Measles-Rubella Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Measles-Rubella Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Measles-Rubella Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Measles / Mumps / Rubella Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Measles / Mumps / Rubella Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Measles / Mumps / Rubella Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Measles Mumps Rubella Varicella Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Measles Mumps Rubella Varicella Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Measles Mumps Rubella Varicella Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for NGOs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for NGOs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for NGOs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Pediatric Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Pediatric Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Pediatric Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Rubella Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • Rubella Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • Rubella Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 52: China 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • Rubella Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Rubella Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Rubella Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Rubella Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • FRANCE
    • Rubella Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 67: France 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • Rubella Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 73: Germany 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 79: Italy 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Rubella Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 85: UK 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 88: Spain 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 91: Spain 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 94: Russia 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 97: Russia 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Rubella Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Rubella Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Rubella Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Rubella Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Rubella Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 115: Australia 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 118: Australia 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • INDIA
    • Rubella Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 121: India 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 124: India 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 127: South Korea 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 130: South Korea 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Rubella Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Rubella Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Rubella Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Rubella Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 145: Latin America 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 148: Argentina 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 151: Argentina 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 154: Brazil 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 157: Brazil 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 160: Mexico 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 163: Mexico 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Rubella Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Rubella Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Rubella Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Rubella Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 178: Middle East 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 181: Iran 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 184: Iran 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 187: Israel 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 190: Israel 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 199: UAE 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 202: UAE 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • AFRICA
    • Rubella Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 211: Africa 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 214: Africa 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION